Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 5

Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide

Authors Carl E Stafstrom

Published Date October 2009 Volume 2009:5 Pages 547—551

DOI http://dx.doi.org/10.2147/NDT.S5300

Published 23 October 2009

Carl E Stafstrom

Section of Pediatric Neurology, Departments of Neurology and Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Objective: This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable epileptic encephalopathy of early childhood. In particular, the review focuses on rufinamide, a recently released anticonvulsant medication with reported effectiveness in this epilepsy syndrome.

Methods: A systematic literature search (PubMed) was performed to review the existing literature pertaining to the treatment of Lennox-Gastaut syndrome as well as studies involving rufinamide as an anticonvulsant medication.

Results: The published literature to date documents a beneficial effect of rufinamide on children over 4 years old with Lennox-Gastaut syndrome. Studies indicate a significant decrease in tonic and atonic seizure frequency as well as total seizure frequency compared to placebo-treated children. Rufinamide appears to be well tolerated and a safe medication, somnolence and vomiting being the most common side effects.

Conclusions: Rufinamide is a promising adjunctive therapy for Lennox-Gastaut syndrome, an intractable childhood epilepsy. To ensure its optimal effectiveness, clinicians must be familiar with the medication’s clinical response profile and potential for adverse effects.

Keywords: pediatric, epilepsy, epileptic encephalopathy, Lennox-Gastaut syndrome, rufinamide

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Aggressive behavior, cognitive impairment, and depressive symptoms in elderly subjects

Margari F, Sicolo M, Spinelli L, Mastroianni F, Pastore A, Craig F, Petruzzelli MG

Neuropsychiatric Disease and Treatment 2012, 8:347-353

Published Date: 1 August 2012

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Tenofovir-associated bone density loss

Iwen F Grigsby, Lan Pham, Louis M Mansky, et al

Therapeutics and Clinical Risk Management 2010, 6:41-47

Published Date: 24 December 2009

Bone resorption in incompletely impacted mandibular third molars and acute pericoronitis

Minoru Yamaoka, Yusuke Ono, Masahiro Takahashi, Ryosuke Doto, et al.

Clinical, Cosmetic and Investigational Dentistry 2009, 1:7-12

Published Date: 14 April 2009